je.st
news
Tag: regimen
Rodan + Fields Launches New Regimen
2020-10-19 20:49:53| Happi Breaking News
Targets major signs of aging in one simple system.
Tags: fields
launches
regimen
rodan
Going Green: How to Create an Eco-Friendly Beauty Regimen
2020-06-01 09:00:00| Waste Age
Globally we need to make a conscious effort to protect our planet. Everything we do impacts the Earth. Yes, even our beauty routines. There are many small changes consumers can make to create an eco-friendly beauty routine. They include:
Tags: create
beauty
green
regimen
Data for Merck's Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
2016-07-22 13:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the companys investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg), from the ongoing Phase 3 pivotal trial called ONCEMRK. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Carmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
New AbbVie hepatitis C regimen shows high cure rates: studies
2016-04-16 14:49:17| Biotech - Topix.net
An experimental once-daily combination hepatitis C treatment being developed by AbbVie Inc demonstrated very high cure rates across a wide range of disease genotypes, according to data presented on Saturday, likely giving the company a more competitive product if approved. Cure rates of 97 percent to 100 percent over either eight or 12 weeks of treatment were achieved in the clinical trials with the one pill, once-a-day combination of ABT-493 and ABT-530, which use different methods to block virus replication.
Tags: high
shows
rates
studies
Mercks ZEPATIER (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
2016-04-14 07:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Results From C-EDGE Head-to-Head Study in Patients with Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The International Liver Congress 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head, the companys comparative, Phase 3, open-label clinical trial evaluating the efficacy and safety of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets versus a regimen of sofosbuvir 400mg tablets plus peginterferon and ribavirin (pegIFN/RBV) in treatment-nave and pegIFN/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infect Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
safety
treatment
trial